Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

Rhea-AI Summary

Stereotaxis (NYSE: STXS) announced a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany, making it the first hospital in Germany to adopt the Genesis Robotic Magnetic Navigation System for arrhythmia care. Physicians have treated initial patients across a range of arrhythmias using the system.

Company executives and Klinikum Fürth clinicians highlighted improved precision, procedural stability, and reduced radiation exposure from less fluoroscopic confirmation. Stereotaxis noted its technology has been used in over 150,000 patients globally and said it will support the hospital's robotic heart rhythm practice.

News Market Reaction – STXS

+4.43%

1 alert

+4.43% News Effect

+$8M Valuation Impact

$189.45M Market Cap

0.9x Rel. Volume

On the day this news was published, STXS gained 4.43%, reflecting a moderate positive market reaction. This price movement added approximately $8M to the company's valuation, bringing the market cap to $189.45M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patients treated with Stereotaxis tech: over 150,000 patients

1 metrics

Patients treated with Stereotaxis tech over 150,000 patients Cumulative usage across United States, Europe, Asia and elsewhere

Market Reality Check

Price: $1.7800 Vol: Volume 470,645 is close t...

normal vol

$1.7800 Last Close

Volume Volume 470,645 is close to the 20-day average of 516,761, suggesting typical trading interest pre-announcement. normal

Technical Shares at $2.03 are trading below the 200-day MA of $2.49 and about 43% under the 52-week high of $3.59.

Peers on Argus

STXS was up 2.53% while peers showed mixed moves: STSS +6.45%, MBOT +6.02%, INFU...

1 Up

STXS was up 2.53% while peers showed mixed moves: STSS +6.45%, MBOT +6.02%, INFU +2.39%, OSUR -2.17%, NYXH -0.64%. Only one peer (MBOT) appeared in the momentum scanner, indicating this looks more stock-specific than a broad sector rotation.

Historical Context

5 past events · Latest: Jan 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 06	FDA approval	Positive	+8.1%	MAGiC ablation catheter received FDA approval for robotic procedures.
Nov 24	Conference participation	Positive	+1.7%	Participation in major healthcare conference highlighting growth and milestones.
Nov 11	Quarterly earnings	Neutral	+2.1%	Q3 2025 results with revenue details and multiple regulatory/commercial updates.
Nov 10	FDA clearance	Positive	+2.6%	GenesisX robotic system obtained U.S. FDA 510(k) clearance for launch.
Oct 21	Earnings announcement	Neutral	-1.6%	Scheduling Q3 2025 results call and webcast with access details.

Pattern Detected

Recent news—mainly regulatory approvals and product/commercial updates—has usually been followed by modest positive price reactions, with only one noted divergence on a conference/earnings-related announcement.

Recent Company History

Over the last few months, Stereotaxis has reported several milestones, including FDA clearance for GenesisX on Nov 10, 2025 and FDA approval for the MAGiC ablation catheter on Jan 6, 2026, both followed by single‑digit percentage gains. Q3 2025 earnings showed $7.5M revenue and highlighted regulatory and commercial progress. Today’s news about a leading German center adopting the Genesis robotic system extends this trajectory of expanding clinical use and supports the recent regulatory wins.

Market Pulse Summary

This announcement highlights expanded real‑world adoption of Stereotaxis’ robotic technology, with K...

Analysis

This announcement highlights expanded real‑world adoption of Stereotaxis’ robotic technology, with Klinikum Fürth establishing a leading arrhythmia program using the Genesis system and joining over 150,000 prior patient treatments globally. In context with recent FDA clearances and Q3 results, it underscores a focus on growing procedure volume and clinical footprint. Investors may watch for future disclosures on procedure trends, revenue impact, and additional center deployments.

Key Terms

endovascular intervention, electrophysiology, Genesis Robotic Magnetic Navigation System, cardiac ablation, +1 more

5 terms

endovascular intervention medical

"leader in surgical robotics for minimally invasive endovascular intervention"

An endovascular intervention is a medical procedure performed through the body's blood vessels using thin tubes, wires and small tools to repair blockages, tighten leaks or open narrowed arteries without large incisions. For investors, these procedures signal demand for specialized devices, imaging systems and hospital services; like fixing a clogged pipe from the inside, they can reduce recovery time and costs, influence reimbursement rates, and drive sales for companies that supply the tools.

electrophysiology medical

"launch of a new robotic electrophysiology program at Klinikum Fürth"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

Genesis Robotic Magnetic Navigation System technical

"program that incorporates the Genesis Robotic Magnetic Navigation System"

A genesis robotic magnetic navigation system is a medical-device platform that uses external magnetic fields and a robotic controller to steer tiny instruments, like catheters, inside the body during minimally invasive heart procedures. Think of it as a remote-controlled magnetic steering system that aims to increase precision and reduce operator fatigue, which can shorten procedure times, lower complication risks, and influence hospitals’ buying decisions, reimbursement prospects, and a device maker’s revenue growth.

cardiac ablation medical

"Robotic Magnetic Navigation introduces the benefits of precision and safety to cardiac ablation"

Cardiac ablation is a medical procedure that uses heat, cold, or energy to destroy small areas of heart tissue that cause abnormal electrical signals and irregular heartbeats. For investors, it matters because the procedure drives demand for specialized medical devices, hospital services, and ongoing treatment revenues, and changes in its safety, effectiveness, or insurance coverage can materially affect companies and clinical adoption—think of it as targeted surgery that resets a misfiring circuit in the heart.

forward-looking statements regulatory

"This press release includes statements that may constitute “forward-looking” statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. Not financial advice.

ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany.

Klinikum Fürth is the first hospital in Germany to establish a leading heart rhythm program that incorporates the Genesis Robotic Magnetic Navigation System, advanced robotic technology that establishes a new standard of care for patients with arrhythmias. Physicians at Klinikum Fürth have successfully treated their first patients, with a wide range of arrhythmias, leveraging the advanced technology.

“We are proud to be the first in our region to offer this cutting-edge robotic technology and look forward to continuing to use the system to treat patients suffering from heart rhythm disorders,” said Dr. Laura Vitali-Serdoz, Head of the Rhythmology & Invasive Electrophysiology at Klinikum Fürth.

“The precision and stability offered by Robotic Magnetic Navigation allows us to successfully treat even the most complex arrhythmias with confidence, which is a major benefit for our team and more importantly for our patients,” said Dr. Dirk Bastian, Deputy Head of the Rhythmology & Invasive Electrophysiology. “The technology is also minimizing the need for fluoroscopic confirmation and thereby reducing radiation exposure.”

Robotic Magnetic Navigation introduces the benefits of precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.

“We are proud to partner with Klinikum Fürth to expand access to minimally invasive arrhythmia care in Germany,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to supporting their successful and impactful robotic heart rhythm practice.”

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, including statements regarding the completion of the Company’s offering and the anticipated use of proceeds therefrom, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. There can be no assurance that the Company will recognize revenue related to customer purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

What did Stereotaxis (STXS) announce on February 9, 2026 about Klinikum Fürth?

Stereotaxis announced the launch of a robotic electrophysiology program at Klinikum Fürth on February 9, 2026. According to the company, Klinikum Fürth is the first hospital in Germany to use the Genesis Robotic Magnetic Navigation System to treat a range of arrhythmias.

How does the Genesis Robotic Magnetic Navigation System affect radiation exposure in procedures at Klinikum Fürth?

The system reduces reliance on fluoroscopic confirmation and can lower radiation exposure for staff and patients. According to the company, robotic precision and stability allow clinicians to confirm device position with less fluoroscopy during cardiac ablation procedures.

Have physicians at Klinikum Fürth treated patients with the Stereotaxis robotic system?

Yes, physicians at Klinikum Fürth have successfully treated their first patients using the robotic system. According to the company, clinicians used the Genesis system to treat a wide range of arrhythmias in initial cases at the hospital.

What patient-care benefits did Klinikum Fürth doctors cite about the robotic heart rhythm program (STXS)?

Clinicians cited improved procedural precision and stability that support treatment of complex arrhythmias. According to the company, those attributes increase operator confidence and may enhance safety during minimally invasive cardiac ablation.

How extensive is Stereotaxis's clinical footprint prior to the Klinikum Fürth program?

Stereotaxis reports its technology has been used to treat over 150,000 patients worldwide. According to the company, that global usage underpins its position as a leader in robotic systems for minimally invasive endovascular intervention.